Related Experiment Video
Updated: May 25, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[New biomarkers in prostate cancer]
1Klinik für Urologie, Abteilung Onkologische Forschung, Universitätsspital Zürich. maurizio.provenzano@usz.ch
Praxis
|January 19, 2012
Summary
Finding better prostate cancer (PCa) biomarkers is crucial. This review examines current and novel biomarkers for improved PCa screening and early detection, aiming for greater accuracy than prostate-specific antigen (PSA) alone.
Area of Science:
- Oncology
- Biochemistry
- Urology
Context:
- Prostate cancer (PCa) is a leading cause of cancer-related death in men globally.
- Current diagnostic and prognostic tools, including prostate-specific antigen (PSA), have limitations in distinguishing indolent from aggressive disease.
- There is an unmet need for sensitive and specific biomarkers for effective PCa screening and early detection.
Purpose:
- To review the utility of established biomarkers like PSA in prostate cancer management.
- To explore emerging biomarkers for improved prostate cancer screening and early detection.
- To discuss the potential of combining biomarkers for enhanced diagnostic accuracy.
Summary:
- Prostate cancer (PCa) diagnosis and management rely heavily on prostate-specific antigen (PSA), despite its limitations.
- Research is ongoing to identify novel biomarkers that can accurately differentiate between indolent and clinically significant PCa.
- This review synthesizes current knowledge on PSA and new biomarkers for potential use in screening and early detection programs.
Impact:
- Improved accuracy in prostate cancer screening and early detection.
- Better patient stratification for treatment and active surveillance decisions.
- Potential reduction in morbidity and mortality associated with prostate cancer.
